Targeting the female endocannabinoid system: A CAM intervention addressing behavioral nutrition and treating depression in women with T2DM
Psychology, National University, La Jolla, CA, USA.
Review Article
GSC Biological and Pharmaceutical Sciences, 2023, 23(03), 128–137.
Article DOI: 10.30574/gscbps.2023.23.3.0203
Publication history:
Received on 13 April 2023; revised on 25 May 2023; accepted on 27 May 2023
Abstract:
The following disquisition utilizes the principles of biomolecular psychology to examine the biopsychological efficacy of nutraceutical medications targeting the Female Endocannabinoid System (FECS), particularly concerning Type 2 diabetic (T2DM) women suffering from depression. Theoretical frameworks of psychoneuroimmunology linked with endocannabinoid deficiency theories and behavioral nutrition provide evidence for the efficacious use of Complimentary Alternative Medicine (CAM) interventions and treatments as a preferred option for women diagnosed with T2DM suffering from chronic depression. From a biomolecular perspective, the iatrogenic effects of synthetic drugs have demonstrated profound disadvantages for the female body. Future direction for research and implementation of alternative dietary plans and botanic cannabinoid supplementation for treating depression and other mood disorders associated with the imbalances of the Female Endocannabinoid System is discussed.
Keywords:
FECS (Female Endocannabinoid System); Biomolecular Psychology; Psychoneuroimmunology; T2DM (Type 2 Diabetes); Depression; CAM (Complimentary Alternative Medicine).
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
